Appeals Court Revives a Florida Medicare Fraud Case and Saves the Whistleblower Law Behind It

The U.S. Court of Appeals for the Eleventh Circuit has reversed a Florida federal judge's ruling that threatened one of the federal government's most effective fraud-fighting tools, holding that the whistleblower provisions of the False Claims Act do not violate the Constitution's Appointments Clause. The decision revives a Medicare Advantage fraud case brought by a Florida physician and removes a cloud that had hung over hundreds of similar cases nationwide.

The case is Zafirov v. Florida Medical Associates LLC. Dr. Clarissa Zafirov, a board-certified family care physician, accused her former employer, doing business as VIPcare, of systematically submitting false Medicare Advantage diagnosis codes in order to inflate the monthly risk-adjustment payments the practice received. In 2024, U.S. District Judge Kathryn Kimball Mizelle dismissed the case, holding that the statute's qui tam mechanism improperly allows private citizens to exercise executive branch authority.

The appeals court disagreed. It held that private whistleblowers who sue on behalf of the United States are not acting as improperly appointed federal officers, vacated the dismissal, and sent the case back to the district court to consider the defendants' remaining constitutional arguments.

What the False Claims Act does

The False Claims Act allows private individuals, known as relators, to file suit on behalf of the federal government against parties they allege have defrauded it. The government then decides whether to intervene and take over the case. If the case succeeds, the relator receives a share of the recovery, typically between 15 and 30 percent depending on whether the government intervened.

The statute dates to the Civil War, when it was enacted to address contractors defrauding the Union Army. It has become the government's primary civil tool against fraud in federal programs, and health care fraud accounts for the largest share of recoveries under it.

The economic logic behind the qui tam mechanism is that fraud against federal programs is usually invisible to the government. A billing scheme inside a medical practice is visible to employees, not to auditors reviewing claims data. The financial incentive is what converts an employee's knowledge into a filed case, and the personal risk is substantial: relators frequently lose their jobs and their industry standing.

The constitutional challenge

Judge Mizelle's 2024 ruling accepted an argument that had been circulating in conservative legal circles for years. The Appointments Clause of Article II requires that officers of the United States be appointed by the President, the courts, or department heads. A relator who litigates on the government's behalf, the argument goes, is exercising the executive power to enforce federal law without having been appointed to any office.

The Eleventh Circuit rejected that framing. Its reasoning is that a relator is not a federal officer. A relator holds no continuing position, exercises no governmental authority beyond prosecuting a single lawsuit, and operates under substantial government control. The Justice Department can intervene, can settle the case over the relator's objection, and can move to dismiss it entirely.

The court also had history on its side. Qui tam statutes existed at the time of the founding, Congress has enacted them repeatedly since, and the Supreme Court has addressed False Claims Act cases many times without suggesting the mechanism was constitutionally infirm.

The ruling is not the complete end of the constitutional dispute. The appeals court vacated the dismissal and remanded so the district court can evaluate the defendants' remaining arguments under the Take Care Clause and the Vesting Clause, theories that were not resolved on appeal.

The underlying fraud allegations

Zafirov's complaint concerns Medicare Advantage risk adjustment, a payment mechanism that is one of the more consequential and least understood parts of American health care finance.

Medicare Advantage plans receive a fixed monthly payment per enrollee rather than payment per service. That payment is adjusted based on the enrollee's documented health conditions, so a plan covering sicker patients receives more. The system is designed to prevent plans from avoiding expensive patients.

It also creates an obvious incentive. Every additional diagnosis code documented for a patient increases the monthly payment, whether or not the patient actually has the condition or receives treatment for it. Zafirov alleges that her former employer systematically submitted diagnosis codes that were not supported by the patients' actual conditions in order to inflate those payments.

Risk adjustment fraud has become one of the largest categories of federal health care fraud enforcement, and the amounts involved are substantial because the inflation applies to every month of every affected enrollee's coverage.

What the statute recovers

The practical argument for the False Claims Act is the money it returns. The Justice Department reports annual recoveries under the statute in the billions of dollars, and the largest share consistently comes from health care cases. Qui tam suits filed by private relators account for the substantial majority of those recoveries.

That ratio is the strongest empirical case for the mechanism the Eleventh Circuit just upheld. Government auditors reviewing claims data can detect statistical anomalies, but they generally cannot distinguish an aggressive but legitimate coding practice from a deliberate scheme without inside knowledge. The employee who was told to add diagnosis codes can.

The government's control over these cases is also more substantial than critics of the mechanism sometimes acknowledge. A qui tam complaint is filed under seal and served on the Justice Department, which investigates before the defendant is even notified. The government decides whether to intervene, and it can move to dismiss a case it considers meritless even over the relator's objection.

Relators who proceed without government intervention face long odds and considerable expense. The share of recoveries they receive is higher in those cases, reflecting the risk. Most declined cases produce nothing at all.

The legal theory and where it came from

The Appointments Clause challenge to qui tam did not appear spontaneously. Justice Clarence Thomas raised the question in a 2023 dissent, suggesting that the constitutionality of the False Claims Act's private enforcement mechanism warranted examination, and two other justices noted the issue merited consideration in an appropriate case.

That signal prompted defendants across the country to raise the argument, and Judge Mizelle's 2024 ruling in the Zafirov case was the first district court decision to accept it. The decision drew immediate national attention precisely because of what it implied for the hundreds of pending qui tam cases.

The Eleventh Circuit's reversal is therefore more consequential than an ordinary appellate decision. It is the first federal appeals court ruling squarely addressing the theory after the Supreme Court signal that generated it, and it comes from the circuit where the district court decision originated.

The court's reasoning emphasized that a relator's authority is limited, temporary and subject to executive control, which distinguishes it from the continuing exercise of sovereign power that defines an officer of the United States under the Appointments Clause. Historical practice, including founding-era qui tam statutes enacted by the first Congresses, reinforced that conclusion.

Why this matters in Florida

Florida is arguably the most important Medicare Advantage market in the country. The state has one of the largest Medicare-eligible populations in absolute terms, and Medicare Advantage penetration in Florida is among the highest of any state. Florida counties routinely appear among the highest in the nation for the share of Medicare beneficiaries enrolled in Advantage plans.

That concentration means Florida is where Medicare Advantage risk adjustment practices have the largest financial footprint and where enforcement activity is heaviest. Both the Southern and Middle Districts of Florida have been active venues for health care fraud prosecutions, and Florida cases regularly feature in national enforcement actions.

For Florida seniors, the practical connection is less about the litigation than about what risk adjustment fraud does to the program. Inflated payments increase Medicare's costs, which contributes to premium and benefit decisions that eventually affect enrollees. Fraudulent diagnosis codes also enter patients' medical records, where they can affect future care decisions and insurability.

What the ruling means going forward

The immediate effect is that Zafirov's case returns to the district court and proceeds. The broader effect is that hundreds of pending False Claims Act cases in the Eleventh Circuit, which covers Florida, Georgia and Alabama, are no longer shadowed by a district court holding that the entire mechanism was unconstitutional.

For health care providers, the ruling removes a defense that had appeared potentially viable and restores the prior status quo. Compliance programs that had been watching the constitutional challenge now have their answer, at least at the circuit level.

For potential whistleblowers, the ruling restores certainty. Filing a qui tam case involves significant personal and professional risk, and the prospect that the statute might be struck down was a genuine deterrent.

The constitutional question is not permanently settled. Other circuits have considered related challenges, and the Supreme Court has not addressed the Appointments Clause theory directly. A circuit split would make eventual Supreme Court review considerably more likely.

What's next

The case returns to the Middle District of Florida, where the district court will take up the Take Care Clause and Vesting Clause arguments the appeals court left open. Those theories are variations on the same separation of powers concern and have generally fared no better than the Appointments Clause argument, but they have not been resolved here.

If those defenses fail, the case proceeds to the merits, meaning whether the diagnosis codes at issue were in fact unsupported and whether the submissions were knowingly false.

The defendants could also seek further review, either from the full Eleventh Circuit sitting en banc or from the Supreme Court. Given the stakes for the False Claims Act and the interest the constitutional theory has attracted, a petition would not be surprising.